Intellia Therapeutics Inc. (NTLA)
Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains?
Intellia Therapeutics (NTLA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Intellia Therapeutics, Inc. (NTLA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Intellia Therapeutics, Inc. (NTLA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 200-Day Moving Average
Intellia Therapeutics, Inc. (NTLA) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, NTLA broke through the 200-day moving average, which suggests a long-term bullish trend.
Intellia Stock Declines Around 55% in 3 Months: Here's Why
NTLA shares plunge 55% in three months after the FDA placed a clinical hold on Nex-Z, suspending trials and milestone guidance following the death of a patient.
Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry?
Intellia advances in vivo pipeline with lonvo-z through its pivotal HAELO study, eyeing mid-2026 data and a potential 2026 filing to propel growth.
NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock?
Intellia sinks 67% in a month after a clinical hold on nex-z and mixed third-quarter results, raising questions about its pipeline outlook and near-term direction.
Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks?
Intellia faces FDA clinical holds on key ATTR studies as it readies crucial HAE data in 2026, making lonvo-z pivotal for its near-term outlook.
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Misses Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to a loss of $1.34 per share a year ago.
Intellia Therapeutics, Inc. (NTLA) Discusses Safety Event and Protocol Pause in MAGNITUDE Clinical Trials of Nex-Z Transcript
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Discusses Safety Event and Protocol Pause in MAGNITUDE Clinical Trials of Nex-Z October 27, 2025 8:30 AM EDT Company Participants Jason Fredette John Leonard - President, CEO & Director David Lebwohl - Executive VP & Chief Medical Officer Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Huidong Wang - Barclays Bank PLC, Research Division Lili Nsongo - Leerink Partners LLC, Research Division Joseph Thome - TD Cowen, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Jay Olson - Oppenheimer & Co. Inc., Research Division Terence Flynn - Morgan Stanley, Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division William Pickering - Sanford C. Bernstein & Co., LLC.
Intellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock?
Intellia Therapeutics (NTLA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Intellia Therapeutics (NTLA) Upgraded to Buy: Here's What You Should Know
Intellia Therapeutics (NTLA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Intellia Therapeutics (NTLA) Outperforming Other Medical Stocks This Year?
Here is how Intellia Therapeutics, Inc. (NTLA) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.
